Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors

Research in Veterinary Science

Volumn 82, Issue 2, 2007, Pages 271-279

  Nakaichi, Munekazu ^a   Yunuki, Toshi ^a   Okuda, Masaru ^a   Une, Satoshi ^a   Taura, Yasuho ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Dog; Invasion; Metastasis; MMP 2; Oronasal; TIMP 2; Tumor

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACANTHOMA; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS POTENTIAL; MOUTH CANCER; NONHUMAN; NOSE CANCER; NOSE CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; ZYMOGRAPHY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DOG DISEASES; DOGS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MELANOMA; MOUTH NEOPLASMS; NOSE NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

CANIS FAMILIARIS;

EID: 33846794892     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2006.07.007     Document Type: Article

References (36)

1. Adamas W.M., Miller P.E., Vail D.M., Forrest L.J., and Mzcewen E.G. An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors. Veterinary Radiology & Ultrasound 39 (1998) 475-481
2. Adamas W.M., Bjorling D.E., Mcanulty J.F., Green E.M., Forrest L.J., and Vail D.M. Outcome of accelerated radiotherapy alone or accelerated radiotherapy followed by exenterration of nasal cavity in dogs with intranasal neoplasia: 53 cases (1990-2002). Journal of American Veterinary Medical Association 227 (2005) 936-941
3. Butler G.S., Butler M.J., and Atkinson S.J. The TIMP-2 membrane type I metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. Journal of Biological Chemistry 273 (1998) 871-880
4. Coughlan A.R., Robertson D.H.L., Burke R., Beynon R.J., and Carter S.D. Isolation and identification of canine matrix metalloproteinase-2 (MMP-2). Veterinary Journal 155 (1998) 231-237
5. Danilewicz M., Sikorska B., and Wagrowska-Danilewicz M. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. Medical Science Monitor 9 (2003) MT42-MT47
6. Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., Nesland J.M., Berner A., Bryne M., and Reich R. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clinical Experimental Metastasis 17 (1999) 799-808
7. Fujise N., Nanashima A., Taniguchi Y., Matsuo S., Hatano K., Matsumoto Y., Tagawa Y., and Ayabe H. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 27 (2000) 19-26
8. Gentilini F., Calzolar C., Turba M.E., Agnoli C., Fava D., Forni M., and Bergamini P.F. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leukemia Research 29 (2005) 1263-1269
9. Gohji K., Fujimoto N., Fujii A., Komiyama T., Okawa J., and Nakajima M. Prignostic significance of circulating matrix metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Research 56 (1996) 3196-3198
10. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. European Journal of Cell Biology 74 (1997) 111-122
11. Haq M., Shaeii A.E., Zervos E.E., and Rosemurgy A.S. In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs. International Journal of Surgical Investigation 1 (2000) 459-465
12. Hirayama K., Yokota H., Onai R., Kobayashi T., Kumata T., Kihara K., Okamoto M., Sako T., Nakade T., Izumisawa Y., and Taniyama H. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. Journal of Comparative Pathology 127 (2002) 249-256
13. Hofmann U.B., Westphal J.R., Zendman A.J., Becker J.C., Ruiter D.J., and Muijen G.N.P. Expression and activation of matrix metalloproteinases-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinases (MT1-MMP) correlate with melanoma progression. Journal of Pathology 191 (2000) 245-256
14. Kallakury B.V., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., and Ross J.S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clinical Cancer Research 7 (2001) 3113-3119
15. Kikuchi R., Noguchi T., Takeno S., Kubo N., and Uchida Y. Immunohistochemical detection of membrane-type-1-matrix metalloproteinases in colorectal carcinoma. British Journal of Cancer 83 (2000) 215-218
16. Kugler A., Hemmerlein B., Thelen P., Kallerhoff M., Radzun H.J., and Ringert R.H. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. Journal of Urology 160 (1998) 1914-1918
17. Ladue T.A., Dodge R., Page R.L., Price G.S., Hauck M.L., and Thrall D.E. Factors influencing survival after radiotherapy of nasal tumors in 130 dogs. Veterinary Radiology & Ultrasound 40 (1999) 312-317
18. Lana S.E., and Withrow S.J. Nasal tumor. In: Withrow S.J., and Macewen E.G. (Eds). Small Animal Clinical Oncology. 3rd ed. (2001), W.B. Saunders, Philadelphia 370-377
19. Lana S.E., Ogilvie G.K., Hansen R.A., Powers B.E., Dernell W.S., and Withrow S.J. Identification of matrix metalloproteinases in canine neoplasmtic tissue. American Journal of Veterinary Research 61 (2000) 111-114
20. Leibman N.F., Lana S.E., Hansen R.A., Powers B.E., Fettman M.J., Withrow S.J., and Ogilvie G.K. Identification of matrix metalloproteinases in canine cutaneous mast tumors. Journal of Veterinary Internal Medicine 14 (2000) 583-586
21. Liotta L.A. Cancer cell invasion and metastasis. Science America 266 (1992) 54-63
22. Loukopoulos P., Mungall B.A., Straw R.C., Thornton J.R., and Robinson W.F. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Veterinary Pathology 40 (2003) 382-394
23. Loukopoulos P., O'Brien T., Ghoddusi M., Mungall B.A., and Robinson W.F. Characterisation of three novel canine osteosarcoma cell lines producing high levels of matrix metalloproteinases. Research in Veterinary Science 77 (2004) 131-141
24. Murray G.I., Duncan M.E., Arbuckle E., Melvin W.T., and Fothergill J.E. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43 (1998) 791-797
25. Nagase H. Cell surface activation of progelatinase A (pro-MMP-2) and cell migration. Cell Research 8 (1998) 179-186
26. Nagase H. Activation mechanisms of matrix metalloproteinases. Biological Chemistry 378 (1999) 100-151
27. O-Charoenrat P., Rhys-Evans P.H., and Eccles S.A. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127 (2001) 813-820
28. Onisto M., Riccio M.P., Scannapieco P., Caenazzo C., Griggio L., Spina M., Stetler W.G., and Garbisa S. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, s measured by RT-PCR. International Journal of Cancer 63 (1995) 621-626
29. Owen L.N. TNM Classification of Tumors in Domestic Animals (1980), World Health Organization, Geneva
30. Papparella S., Restucci B., Paciello O., and Maiolino P. Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. Journal of Comparative Pathology 126 (2002) 271-276
31. Patnaik A.K. Canine sinonasal neoplasms: clinicopathological study of 285 cases. Journal of American Animal Hospital Association 25 (1989) 103-114
32. Sato H., Takino T., and Okada Y. A matrix metalloproteinases expressed on the surface of invasive tumor cells. Nature 370 (1994) 61-65
33. Sutinen M., Kainulainen T., Hurskainen T., Vesterlund E., Alexander J.P., Overall C.M., Sorsa T., and Salo T. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. British Journal of Cancer 77 (1998) 2239-22345
34. Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer 89 (2003) 1270-1275
35. Will H., Atkinson S.J., Butler G.S., Smith B., and Murphy G. The soluble catalytic domain of membrane type I matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. Journal of Biological Chemistry 271 (1996) 17119-17123
36. Withrow S.J. Cancer of the oral cavity. In: Withrow S.J., and Macewen E.G. (Eds). Small Animal Clinical Oncology. 3rd ed. (2001), W.B. Saunders, Philadelphia 305-318